Management of Breast Cancer in the Genome Era
- 1 February 2009
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 60 (1) , 153-165
- https://doi.org/10.1146/annurev.med.60.061107.145152
Abstract
The genomic era has been characterized by an exponential increase in the number of targets in the management of breast cancer. Prognostic profiling has helped to determine which tumors are more likely to be associated with poor disease-free survival. Gene expression profiles are being studied in order to improve predictions of response and toxicity. Epigenetics is being evaluated for its ability to influence estrogen receptor expression. However, these fields require further validation. This review discusses the advances in the management of breast cancer through genomic evaluation.Keywords
This publication has 53 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 2006
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000